FWM
HRTX icon

Filbrandt Wealth Management’s Heron Therapeutics HRTX Stock Holding History

Filbrandt Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15
Closed – – 188
2021
Q1 		$0 Buy
+15
New +$267 ﹤0.01% 190

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Filbrandt Wealth Management's HRTX Position: Q2 2021 in Review

Filbrandt Wealth Management sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 15 shares.

Filbrandt Wealth Management first reported a position in HRTX in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

  • Filbrandt Wealth Management reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Filbrandt Wealth Management sold 15 Heron Therapeutics shares in Q2 2021.
  • Filbrandt Wealth Management first reported a position in Heron Therapeutics in Q1 2021 and held it in 1 quarter.
  • Filbrandt Wealth Management's Heron Therapeutics position peaked at $0 in Q1 2021.
  • 189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on Filbrandt Wealth Management's 13F filing for Q2 2021, filed 7 Jul 2021.